Wells Investment

Testworks is a social enterprise company in Seoul, Korea. We create innovative solutions in AI data and software testing fields while providing an inclusive employment model for socially disadvantaged people. Our technical excellence ranges from AI data processing automation to manual software testing and review. We are recognized as the best-in-class data processing company for building high quality datasets used for AI training and verification.

Anipen is a South Korean company focused on developing a 3D content platform that leverages augmented reality and deep learning technologies. The company specializes in creating applications for short video platforms and video games, enabling businesses to produce augmented reality web TV shows, social media promotional videos, and animated clips accessible on mobile devices. Anipen's innovative solutions facilitate the development of video communication and entertainment platforms, allowing enterprises to effectively promote their products and engage with their audiences.

Ingine Inc. is a technology company based in Seoul, South Korea, founded in 2017. It specializes in developing a wave energy converter known as INwave, which efficiently converts tidal energy from waves into electricity. This innovative technology is particularly effective in shallow waters, where traditional converters face challenges. By harnessing the full range of wave movements, Ingine's solution enables clients to generate power reliably, expanding the potential for renewable energy generation in diverse marine environments.

Neurophet, Inc. is a neuroscience company based in Seoul, South Korea, founded in 2016. It specializes in developing innovative software solutions for brain stimulation and treatment of neurological disorders. The company's flagship product, Neurophet tES Lab, is a simulation software that calculates and visualizes the effects of brain stimulation by utilizing individual brain structures and specific stimulation conditions. Neurophet employs its proprietary Segengine technology, which can automatically segment brain magnetic resonance images into 107 distinct regions within a minute. This technology aids in predicting and investigating stimulation effects for conditions such as Alzheimer's disease, providing clinicians with a three-dimensional brain model and stimulation parameter guidance. By leveraging deep learning and numerical optimization techniques, Neurophet enables healthcare professionals to focus interventions on targeted regions of the brain, enhancing treatment efficacy for patients with brain diseases.

3billion, Inc. offers genetic testing and analysis services specifically designed for patients with rare diseases. Founded in 2016 and headquartered in Seoul, South Korea, the company aims to alleviate the challenges faced by these patients during the diagnostic process. By leveraging bioinformatics and machine learning technology, 3billion has significantly reduced the time and cost associated with genome interpretation, making comprehensive genetic testing more accessible. Their artificial intelligence-driven diagnostic services cover a wide range of genes and diseases, facilitating faster and more accurate diagnoses for healthcare providers, ultimately leading to improved health outcomes for patients.

Ziptoss is transforming the South Korean real estate sector by offering a free brokerage service tailored for tenants. The company provides a platform that delivers transparent information and reliable offline fees, making the rental process more accessible. Ziptoss's application allows users to access online listings and advertisements while facilitating brokerage services specifically for foreigners. By gathering data directly from landlords, Ziptoss enables tenants to secure accommodations without incurring third-party fees, thereby streamlining the rental experience and enhancing transparency in the market.

Fount Inc. is an asset management Robo-Advisor company established in 2015 and headquartered in Seoul, South Korea. The firm specializes in providing customized financial portfolios through its advanced Robo-Advisor engine, Bluewhale, which utilizes AI technology and asset allocation theories to determine the optimal mix of assets. Fount's investing algorithm, driven by big data, assists clients in planning for various life events by promoting passive investing strategies that align with individual risk tolerance and time horizons. The company's tools enable clients to monitor financial markets and adjust their asset allocations in response to market fluctuations.

CastingN Co., Ltd is an online sourcing platform based in Incheon, South Korea, established in 2015. It connects companies with professional subcontractors across various sectors, facilitating the outsourcing of services such as advertising, system development, web design, and accounting. The platform evaluates multiple factors, including company history, performance, and feedback, to identify the most suitable subcontractors for clients' needs. In addition to its matching services, CastingN offers programs for developing job-oriented content and conducting offline job training, enabling companies to work efficiently with specialized service providers.

3billion, Inc. offers genetic testing and analysis services specifically designed for patients with rare diseases. Founded in 2016 and headquartered in Seoul, South Korea, the company aims to alleviate the challenges faced by these patients during the diagnostic process. By leveraging bioinformatics and machine learning technology, 3billion has significantly reduced the time and cost associated with genome interpretation, making comprehensive genetic testing more accessible. Their artificial intelligence-driven diagnostic services cover a wide range of genes and diseases, facilitating faster and more accurate diagnoses for healthcare providers, ultimately leading to improved health outcomes for patients.

MDimune Inc. is a therapeutics company based in Seoul, South Korea, established in 2015. It specializes in developing innovative drug delivery systems, particularly utilizing vesicles derived from immune and stem cells. The company focuses on creating targeted delivery methods to enhance the efficacy of treatments for conditions such as cancer, osteoarthritis, chronic obstructive pulmonary disease, and neurodegenerative diseases. MDimune's BioDrone platform enables the manufacture and supply of these vesicles, allowing biotechnology and pharmaceutical firms to develop novel therapeutics aimed at delivering drugs precisely to target tissues. This approach facilitates the provision of advanced anticancer therapies to patients, aligning with the company's mission to improve treatment outcomes through smart drug delivery solutions.

Perseus Inc. specializes in the development of security software tailored for the automotive industry. Founded in 2016 and headquartered in Seoul, South Korea, with additional offices in San Jose, California, and Munich, Germany, the company focuses on enhancing automobile infrastructure through innovative hypervisor technology. This technology allows multiple applications to operate from a single System on Chip (SoC), significantly reducing the number of SoCs needed in connected cars, which can lead to substantial savings and a simpler, more secure ecosystem. The solutions offered by Perseus include a hypervisor-based security system that minimizes in-car hardware and software complexity, a secure container replicating ARM TrustZone functionality, and a Linux fast boot feature that accelerates boot-up times for embedded devices. The company ensures robust security with a guarantee of performance even in the event of an operating system attack, providing flexible and real-time control over security parameters.

3billion, Inc. offers genetic testing and analysis services specifically designed for patients with rare diseases. Founded in 2016 and headquartered in Seoul, South Korea, the company aims to alleviate the challenges faced by these patients during the diagnostic process. By leveraging bioinformatics and machine learning technology, 3billion has significantly reduced the time and cost associated with genome interpretation, making comprehensive genetic testing more accessible. Their artificial intelligence-driven diagnostic services cover a wide range of genes and diseases, facilitating faster and more accurate diagnoses for healthcare providers, ultimately leading to improved health outcomes for patients.

Moin, Inc. is a company based in Seoul, South Korea, that specializes in a blockchain-based foreign remittance solution. The firm offers a global money transfer service that is designed to be fast, convenient, and cost-effective, particularly focusing on countries in Asia. Moin's platform leverages blockchain technology to facilitate user-centric international remittance services, allowing customers to transfer money abroad efficiently and at reasonable charges.

Moin, Inc. is a company based in Seoul, South Korea, that specializes in a blockchain-based foreign remittance solution. The firm offers a global money transfer service that is designed to be fast, convenient, and cost-effective, particularly focusing on countries in Asia. Moin's platform leverages blockchain technology to facilitate user-centric international remittance services, allowing customers to transfer money abroad efficiently and at reasonable charges.

G+FLAS Life Sciences Co., Ltd., founded in 2014 and based in Seoul, South Korea, specializes in agricultural biotechnology with a focus on genome editing applications. Utilizing advanced CRISPR-Cas technology, the company develops innovative products such as glycoengineered humanized plants, which involve the selective removal of glycosylation-related genes. A flagship product is the vitamin D3-enriched tomato, aimed at enhancing nutritional value and addressing market demand for functional foods. This product not only serves the health-conscious consumer but also provides a plant-based alternative to traditional vitamin D supplements, catering to various dietary needs. G+FLAS has established a strategic partnership with Bayer, facilitating the commercialization of its technology and enhancing its position in the agricultural market. The company is also engaged in drug research and development, utilizing its gene therapy expertise to support healthcare organizations and pharmaceutical companies. G+FLAS Life Sciences is well-positioned for growth, targeting significant market share and aiming to accelerate expansion in the U.S. and beyond.